PTK2 and gastric cancer: FAK inhibition has been identified to enhance chemotherapy sensitivity and promote anticancer effects, primarily through the activation of p53 transcriptional activity, making it a potential focal point for therapeutic strategies in gastric cancer management and a valuable prognostic indicator in clinical settings [155].